Previous 10 | Next 10 |
The Phase I safety and pharmacokinetic study in 24 healthy volunteers has completed enrollment. The study is still blinded, but only 5 minor adverse events requiring no treatment have been reported in the entire study to date, similar to the safety profile observed in Sorrento’s CO...
Scilex, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics (NASDAQ:SRNE -3.2%) announced that Elizabeth Czerepak will join the company as executive VP, CFO and Chief Business Officer, effective May 18, 2022. Ms. Czerepak will be a member of the Scilex a...
SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), who is a commercial biopharmaceutical company...
PALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developin...
Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...
Scilex Holding Co., a subsidiary of Sorrento Therapeutics (NASDAQ:SRNE), is expanding its direct distribution network to national and regional wholesalers and pharmacies. Scilex said the move gives it better control over distribution of its lidocaine patch Ztildo and to launch future products...
PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developin...
Sorrento Therapeutics (NASDAQ:SRNE) announced on Monday that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application (IND) to study intravenous STI-9167 (COVISHIELD) in healthy volunteers. The Phase 1 study will proceed at a single trial site in the U.S., ...
FDA granted IND clearance today for STI-9167 (Intravenous COVISHIELD™) for a Phase 1 safety and pharmacokinetic study in healthy volunteers. Initial trials are expected to be followed by a multinational Phase 2/3 trial in both mild and moderate COVID-19 patients. STI-9167 h...
SAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participat...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...